The FAST-EU pilot gives sponsors of multinational clinical trials a faster route through the European approval system, and an explainer updated on 4 November shows how it now operates. The initiative, whose name stands for Facilitating and Accelerating Strategic Clinical Trials, runs under the Clinical Trials Regulation and inside the CTIS portal. The Heads of Medicines Agencies, the Clinical Trials Coordination Group and MedEthics EU run it together.
The headline promise is speed. According to the published guidance, the FAST-EU pilot sets a maximum overall timeline of 10 weeks, or 70 calendar days, from CTIS submission to final conclusion, and that period includes the time sponsors take to answer questions. The pilot began on 30 January 2026 with a planned duration of one year. Participation is voluntary, only a limited number of applications are accepted each month, and acceptance is not guaranteed.
The mechanism relies on doing steps at the same time. The FAST-EU pilot uses parallel validation and assessment, a stronger role for the Reporting Member State, and ethics committee opinions from every participating country built into one process. A selection committee of coordination group and MedEthics EU members, together with the proposed reporting state, picks the trials. Sponsors who receive an invitation must reply within five business days.
Eligibility is narrow by design. The FAST-EU pilot accepts initial applications for trials in more than one member state, covering all categories of investigational medicines, provided the dossier is finished and ready for CTIS. It excludes single-country trials, partial submissions, resubmissions of lapsed or rejected applications, substantial modifications and later additions of member states. Sponsors send expressions of interest during monthly windows, and the December window runs from 19 to 20 November with a response due on 27 November.
The 4 November update added a section on how reporting roles are spread. Italy, Denmark, the Netherlands, Germany, Finland, Poland, Sweden, Spain, Belgium, Norway and Czechia have completed or ongoing roles, while Romania, Hungary, Austria and Portugal are planned. Roughly two dozen countries take part, although the explainer is inconsistent about which states are in, so sponsors should check the official lists before relying on them.
The pilot matters because of the political debate around it. Health ministers met informally in Dublin on 1 October under the Irish Presidency to discuss manufacturing capacity and a better clinical trials environment, and Irish Health Minister Jennifer Carroll MacNeill said the aim is for more patients from smaller countries to join larger trials. Health Commissioner Olivér Várhelyi was present, and a formal ministerial meeting is expected in December. The guidance states that the FAST-EU pilot supports future implementation of the EU Biotech Act.
One caveat applies. The most detailed description available comes from a third-party explainer rather than a press release from the European Medicines Agency or the Commission, and no official has quoted figures on how many trials have joined. Whether the FAST-EU pilot becomes a permanent model will depend on the results sponsors and regulators report once the one-year run ends in early 2027.
